ML417
CAS No. 1386162-69-1
ML417( —— )
Catalog No. M21975 CAS No. 1386162-69-1
ML417 is a selective and brain penetrant agonist of D3 Dopamine (EC50 : 38 nM).Molecular modeling suggests that ML417 interacts with the D3R in a unique manner, possibly explaining its remarkable selectivity.?
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 31 | Get Quote |
|
| 5MG | 50 | Get Quote |
|
| 10MG | 88 | Get Quote |
|
| 25MG | 174 | Get Quote |
|
| 50MG | 320 | Get Quote |
|
| 100MG | 474 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameML417
-
NoteResearch use only, not for human use.
-
Brief DescriptionML417 is a selective and brain penetrant agonist of D3 Dopamine (EC50 : 38 nM).Molecular modeling suggests that ML417 interacts with the D3R in a unique manner, possibly explaining its remarkable selectivity.?
-
DescriptionML417 is a selective and brain penetrant agonist of D3 Dopamine (EC50 : 38 nM).Molecular modeling suggests that ML417 interacts with the D3R in a unique manner, possibly explaining its remarkable selectivity.?ML417 was also found to protect against neurodegeneration of dopaminergic neurons derived from iPSCs.?Together with promising pharmacokinetics and toxicology profiles, these results suggest that ML417 is a novel and uniquely selective D3R agonist that may serve as both a research tool and a therapeutic lead for the treatment of neuropsychiatric disorders.
-
In VitroML417 exhibits a Ki for the D3R of 1.24 μM. ML417 is a full and potent agonist for multiple signaling pathways associated with D3R activation.ML417 potently inhibits cAMP accumulation with an EC50 of 86 nM and an efficacy identical to that of dopamine. ML417 exhibits submicromolar affinity for only three of the targets, the β1-adrenergic, 5-HT2B serotoninergic, and σ-1 receptors. ML417 stimulates β-arrestin recruitment to the D3R-WT with an EC50 of 1.4 nM.ML417 protects (0.005-5 μM; 24 hours) D3R-expressing dopaminergic neurons from 6-OHDA induced cell death.
-
In VivoIn vivo pharmacokinetics experiments in mice (using 20 mg/kg; i.p.) reveals that ML417 is brain penetrant and exhibits a plasma half-life of 3.44 hours and a brain half-life of 4.23 hours. ML417 displays a plasma Tmax of 0.5 hours and Cmax of 6500 ng/ml, and a brain Tmax of 0.25 hours and Cmax of 28000 ng/ml. Animal Model:6-8 week old male C57BL/6 mice Dosage:20 mg/kg Administration:I.p. (Pharmacokinetic Analysis)Result:Brain penetrant and exhibits a plasma half-life of 3.44 hours and a brain half-life of 4.23 hours. Displayed a plasma Tmax of 0.5 hours and Cmax of 6500 ng/ml, and a brain Tmax of 0.25 hours and Cmax of 28000 ng/ml.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorD3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1386162-69-1
-
Formula Weight379.45
-
Molecular FormulaC22H25N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:50 mg/mL (131.77 mM; Need ultrasonic)
-
SMILESCOc1ccc(OCCN2CCN(CC2)C(=O)c2cc3ccccc3[nH]2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Moritz AE, et al. Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist. J Med Chem. 2020;63(10):5526‐5567.
molnova catalog
related products
-
ACEPROMAZINE MALEATE
ACEPROMAZINE MALEATE is a dopamine receptor antagonist.
-
Perphenazine dihydro...
Perphenazine dihydrochloride is an orally active dopamine receptor and histamine-1 receptor antagonist that acts on D2 (Ki: 0.56 nM), D3 (Ki: 0.43 nM), and 5-HT2A (Ki: 0.6 nM) receptors, and also binds Alpha-1A adrenergic receptors.
-
Gemcitabine monophos...
Gemcitabine monophosphate disodium salt is a monophosphate derivative of Gemcitabine.
Cart
sales@molnova.com